MM&M Awards finalists unveiled next week

Share this article:
The judges' scores are in for the MM&M Awards 2008 submissions and the shortlist of finalists in each category will be revealed simultaneously in the News Brief and at mmm-online.com next Tuesday, July 22.

Yesterday, more than 40 of the finest leaders and thinkers in healthcare marketing converged on a hotel in midtown New York to review and score a record-breaking 831 entries to the program.

The esteemed judging panel included Deborah Dunsire, president and CEO of Millennium Pharmaceuticals; Joe Shields, product director at Wyeth; Meryl Weinreb, director of patient programs, oncology, at AstraZeneca; Cynthia North, customer marketing director at Bayer HealthCare Pharmaceuticals; Ben Lei, group product manager at Genentech; Joan Mikardos, media director at Sanofi-Aventis; Jennifer Rinaldo, director of marketing at Forest Labs; Mike Pucci, VP, external advocacy at GlaxoSmithKline; Kevin Nalty, product director at Merck; and Stephen Calabrese, associate director of emarketing at Novartis Oncology.

Agency executives were also well-represented, including Doug Burcin, worldwide managing director at Euro RSCG Life Worldwide; Richard Nordstrom, CEO of McCann Healthcare Worldwide; and Sam Welch, CEO of Saatchi & Saatchi Healthcare Communications Group.

Experts from the media space included Jack Barrette, CEO of Wego Health; Marjorie Martin, SVP, general manager at Everyday Health; Bob Ziltz, publisher of Prevention magazine; and Keith Yokum, director of online advertising for the New England Journal of Medicine.

The 24 winners will once again be kept under wraps—even the judges won't know who they are—until the spectacular awards presentation evening at New York's Tavern on the Green on October 30, 2008. Tickets go on sale next week.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.